Subs	itute for	Form U.S. DEPARTMENT OF COMM	ERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER							
PTO-	1390	TRANSMITTAL LETTER T	ATTORNEY'S DOCKET NUMBER								
		DESIGNATED/ELECTED C		1032013-000120 U.S. APPLICATION NO. (If known, see 37 CFR 1.5)							
		CONCERNING A FILING U	,	-							
NT	ERN	ATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	10/531,900 PRIORITY DATE CLAIMED							
		PCT/FR2003/003122	21 October 2003	21 October 2002							
ΓΙΤΙ	E OF	FINVENTION	2. 00.050. 2000	21 0000001 2002							
US	USE OF TENATOPRAZOLE FOR THE TREATMENT OF GASTROESOPHAGEAL REFLUX DISEASE										
API	APPLICANT(S) FOR DO/EO/US										
Francois SCHUTZE, Suzy CHARBIT, Herve FICHEUX, Michel HOMERIN, Alain TACCOEN and Yoshio INABA											
		olicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:									
1.	Ц	This is a FIRST submission to items	concerning a filing under 35 U.S.C. 371.								
2.	×	This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.									
3.		This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (22) indicated below.									
4.		The US has been elected by the expi	iration of 19 months from the priority date (Artic	le 31).							
5.	П	A copy of the International Applicatio									
	_		only if not communicated by the International Bi								
		. —		ureau).							
		b. Las been communicated by									
		c. is not required, as the application was filed in the United States Receiving Office (RO/US).									
6.		An English language translation of th	e International Application as filed (35 U.S.C. 3	71(c)(2))							
		a. is attached hereto.									
		b. has been previously submitte	ed under 35 U.S.C. 154(d)(4).								
7.		Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))									
		a. are attached hereto (required only if not communicated by the International Bureau).									
		have been communicated by the International Bureau.									
		c. have not been made; however, the time limit for making such amendments has NOT expired.									
		b. have not been made and will not be made.									
0											
		An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).									
9.	×	An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).									
10.		on English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).									
	Item	ns 11 to 21 below concern docume	nt(s) or information included:								
11.		An Information Disclosure Statement	under 37 CFR 1.97 and 1.98.								
12.		An assignment document for recording	ng. A separate cover sheet in compliance with	37 CFR 3.28 and 3.31 is included.							
13.		A FIRST preliminary amendment.									
14.		A SECOND or SUBSEQUENT prelin	ninary amendment.	le.							
15.		A substitute specification.									
16		A change of power of attorney and/o	r address letter.								
17		A computer-readable form of the seq	uence listing in accordance with PCT Rule 13to	er.2 and 37 C.F.R. 1.821 - 1.825.							
18		second copy of the published international application under 35 U.S.C. 154(d)(4).									
19		second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).									
20	×	Other items or information: A Request for a Three-Month Extension of Time; A copy of Notification of Missing Requirements dated 20 October 2005; and Response to Notification of Missing Requirements under 35 U.S.C. 371 dated 20 October 2005									
		zo colosof zood, and frespon	ise to Notification of Wissing Requirements und	5. 55 5.6.5. 51 1 Gales 20 October 2005							
•											

	APPLICATION NO. (If known, 10/531,900		CT/FR2003/00312		CKINI	1032013-000	
						CALCULATIONS	PTO USE ONL
21.	Applicant(s) requests that the published application include the following assignment information:						
	**						
	·						
.							
22. 🔀	22. X The following fees are submitted:						
B	asic Filing Fee (1631)						
	Surcharge of \$130.00 (1617) for furnishing the oath or declaration later than months from the earliest claimed priority date (37 CFR 1.492(e)).					\$ 130.00	
_	CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$		
To	otal Claims	-20 =	0	× \$50.00 (16		\$ 0.00	
_	dependent Claims	-3 =	0	× \$200.00 (10		\$ 0.00	
М	MULTIPLE DEPENDENT CLAIM(S) (if applicable) + \$360.00 (1616)						
E	kamination Fee			+ \$200.00 (1			
_	earch Fee			⁺ \$500.00 (1	632)		
<u>A</u>	App. Size Fee (add \$250.00 for each add'l 50 sheets exceeding 100 sheets)						
_			TOTAL OF ABOVI		DNS	\$ 130.00	
	Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.					\$ 0.00	
SUBTOTAL =					TAL =	\$ 130.00	
Processing fee of \$130.00 (1618) for furnishing the English translation later than 20 30 months from the earliest claimed priority date (37 CFR 1.492(f)).						\$ 0.00	
TOTAL NATIONAL FEE =					FEE =	\$ 130.00	
	Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 (8021) per property +						
TOTAL FEES ENCLOSED =						\$ 130.00	
						Amount to be	
_						refunded :	
	a. A check in the amount of to cover the above fees is enclosed.					charged :	
b. Please charge my Deposit Account No. <u>02-4800</u> in the amount of duplicate copy of this sheet is enclosed.						to cover the above	e fees. A
c. The Commissioner is hereby authorized to charge any additional fees which may be required. Deposit Account No. <u>02-4800</u> . A duplicate copy of this sheet is enclosed.						ed, or credit any ov	erpayment to
d.	d. X Charge \$\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \						
	NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a pe or (b)) must be filed and granted to restore the application to pending status.						CFR 1.137(a)
	MKAYPAGH 00000130 1053	•	pg c				
1617		130.00 OP					
	END ALL CORRESPOND			- 0	,		
	$\mathcal{W}_{\mathcal{A}}$.W) land	_
	Buchanan Ingersoll PC Including attorneys from Burns, Doane, Swecker & Mathis SIGNATURE						
Р	P.O. Box 1404						
					Me	elissa M. Haywo	oπn
(7	(703) 836-6620 NAME						
				<u>45,</u>	774	17 M	larch 2006
				REGISTRA	ATION	NO.	DATE

Application No.: 10/531,900 Attorney Docket No.: 032013-120

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of			
Francois SCHUTZE et al.	Group Art Unit:		
Application No.: 10/531,900	Examiner:		
International Filing Date: April 21, 2005	Confirmation No.:		
For: Use of Tenatroprazole for the Treatment of Gastroesophageal Reflux Disease)))		
	1		

RESPONSE TO NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. § 371 DATED 20 OCTOBER 2005

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Please note that inventor Alain Taccoen is deceased. Accordingly, pursuant to 37 C.F.R. §1.421 and MPEP § 409.01(a), his heir, Nathalie Taccoen, has signed on his behalf as heir and legal representative to Alain Taccoen.

Accordingly, Applicants submit herewith the attached executed declaration indicating the relationship between the heir and the deceased inventor and the heir's citizenship, residence, and mailing address as required under 37 C.F.R. § 1.497(b)(2).

The heir is as follows:

Nathalie Taccoen
wife of and heir and legal representative to Alain Taccoen
9, avenue de Villiers
F-78150 Le Chesnay
France

As the heir to Alain Taccoen's estate, Nathalie Taccoen has executed the attached oath/declaration in place of Alain Taccoen.

If there are any questions regarding this submission, please contact the undersigned.

Respectfully submitted,

BUCHANAN INGERSOLL PC

Rv.

Melissa M. Hayworth Programmer Registration No. 45,774

P.O. Box 1404 Alexandria, Virginia 22313-1404 (703) 836-6620

Date: Mar 17, 2006